Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT07209475

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

Led by Royal Biologics · Updated on 2025-10-07

248

Participants Needed

8

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs). The study will evaluate Amnio-Maxx® Dual Layer Amnion Patch.

CONDITIONS

Official Title

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older, with at least 50% of participants being over 65 years old
  • History of Type I or Type II Diabetes Mellitus treated with oral medications and/or insulin
  • Presence of diabetic foot ulcer Wagner grade 1 or 2 located at or below the medial malleolus
  • Ulcer present for more than 4 weeks but less than 12 months if treated with active standard of care
  • Less than 20% healing during a two-week screening period
  • Ulcer size between 1.0 cm2 and 25 cm2 after debridement at first treatment visit
  • Prior infection of ulcer or limb must be treated and controlled following IDSA Guidelines Grade 1
  • Ability and willingness to follow the study protocol
  • Signed informed consent
  • Adequate circulation to affected foot demonstrated by TCOM, SPP, ABI, or TBI within 3 months
  • Negative pregnancy test for females of childbearing potential and agreement to use contraception
  • Ulcer offloaded with protocol-defined device for at least 14 days before randomization
  • Ulcer has a clean base and is free of necrotic debris at treatment product placement
Not Eligible

You will not qualify if you...

  • Life expectancy less than 1 year
  • Ulcer present for more than 1 year
  • Lack of adequate 2-week historical data showing less than 20% area reduction
  • Unable to comply with offloading device
  • Conditions or history compromising ability to complete study or poor adherence to medical treatment
  • Ulcers completely necrotic or fibrotic tissue
  • Major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care, or sickle cell anemia
  • Currently treated for active malignant disease or history of malignancy within the ulcer
  • Other conditions that may compromise safety as judged by Principal Investigator
  • Known allergies or contraindications to amniotic tissue membranes or Amnio-Maxx components
  • Participation in another clinical trial with investigational drug or device interfering with this study
  • Ulcer area reduced by 20% or more after 2 weeks of standard care prior to randomization
  • Pregnant or breastfeeding
  • More than two weeks of immunosuppressant treatment or recent use of chemotherapy or topical steroids on ulcer
  • Ulcer previously treated with tissue engineered or scaffold materials within 30 days before first treatment visit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

Lion Heart Clinical Research

Burbank, California, United States, 91501

Actively Recruiting

2

Royal Research South

Miami, Florida, United States, 33150

Actively Recruiting

3

Denali Health Atlanta, LLC

Stone Mountain, Georgia, United States, 30083

Actively Recruiting

4

SerenaGroup Research Center

Omaha, Nebraska, United States, 68114

Actively Recruiting

5

Suffolk Foot and Ankle

East Patchogue, New York, United States, 11772

Actively Recruiting

6

Wound Care of Tulsa

Tulsa, Oklahoma, United States, 74135

Actively Recruiting

7

VAST Clinical Research Carrollton Foot Center

Carrollton, Texas, United States, 75010

Actively Recruiting

8

Elite Foot & Ankle Associates

Spicewood, Texas, United States, 78669

Actively Recruiting

Loading map...

Research Team

N

Nicole Schrecngost

CONTACT

G

Greg Cosentino

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here